Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Suppression of AMPK activation via S485 phosphorylation by IGF-I during
hyperglycemia is mediated by AKT activation in vascular smooth muscle cells.
Authors
Ning J, Xi G, Clemmons DR
Submitted By
Richard McIndoe on 2/22/2012
Status
Published
Journal
Endocrinology
Year
2011
Date Published
8/1/2011
Volume : Pages
152 : 3143 - 3154
PubMed Reference
21673100
Abstract
As a metabolic sensor, the serine/threonine protein kinase AMP-activated protein
kinase (AMPK) promotes the adaptation of cells to signals arising from
nutrients, hormones, and growth factors. The ability of IGF-I to stimulate
protein synthesis is suppressed by AMPK, therefore, these studies were
undertaken to determine whether IGF-I modulates AMPK activity. IGF-I
dose-dependently suppressed phosphorylation of AMPK T172, and it stimulated AMPK
S485 phosphorylation in vascular smooth muscle cells (VSMC). To determine
whether stimulation of AMPK S485 phosphorylation was mediating this response,
VSMC were transduced with a mutant AMPKa (AMPK S485A). Expression of this
altered form inhibited the ability of IGF-I to suppress AMPK T172 activation,
which resulted in inhibition of IGF-I-stimulated phosphorylation of P70S6
kinase. In contrast, expression of an AMPK S485D mutant resulted in constitutive
suppression of AMPK activity and was associated with increased IGF-I-stimulated
P70S6K phosphorylation and protein synthesis. The addition of a specific AKT
inhibitor or expression of an AKT1 short hairpin RNA inhibited AMPK S485
phosphorylation, and it attenuated the IGF-I-induced decrease in AMPK T172
phosphorylation. Exposure to high glucose concentrations suppressed AMPK
activity and stimulated S485 phosphorylation, and IGF-I stimulated a further
increase in S485 phosphorylation and AMPK T172 suppression. We conclude that
AMPK S485 phosphorylation negatively regulates AMPK activity by modulating the
T172 phosphorylation response to high glucose and IGF-I. IGF-I stimulates S485
phosphorylation through AKT1. The results suggest that AMPK plays an inhibitory
role in modulating IGF-I-stimulated protein synthesis and that IGF-I must
down-regulate AMPK activity to induce an optimal anabolic response.
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!